Act Two Investors LLC Invests $15.81 Million in Stryker Corporation $SYK

Key Points

• Act Two Investors LLC purchased 50,217 Stryker shares worth approximately $15.81 million, making the stock 3.2% of its portfolio. Institutional investors and hedge funds collectively own 77.09% of Stryker.
• Stryker reported quarterly EPS of $3.69, exceeding estimates of $3.49, while revenue rose 9.4% year over year to $6.59 billion. The company also declared a quarterly dividend of $0.88 per share, equivalent to a 1.1% annualized yield.
• Analysts maintain a “Moderate Buy” consensus rating with an average price target of $386.28, despite several recent target reductions. Insiders sold about $98.5 million of shares over the past 90 days.

Act Two Investors LLC purchased a new position in Stryker Corporation (NYSE:SYK - Free Report) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 50,217 shares of the medical technology company's stock, valued at approximately $15,810,000. Stryker accounts for approximately 3.2% of Act Two Investors LLC's holdings, making the stock its 14th biggest position.

Other institutional investors and hedge funds have also bought and sold shares of the company. Gables Capital Management Inc. acquired a new stake in shares of Stryker in the second quarter worth $25,000. Godfrey Financial Associates Inc. acquired a new stake in Stryker during the 4th quarter worth about $26,000. Sankala Group LLC purchased a new position in shares of Stryker during the 4th quarter valued at about $26,000. United Financial Planning Group LLC acquired a new position in shares of Stryker in the 3rd quarter valued at about $27,000. Finally, Atlas Capital Advisors Inc. acquired a new position in shares of Stryker in the 4th quarter valued at about $27,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Trading Up 0.1%

Shares of NYSE:SYK opened at $331.96 on Wednesday. The business's 50 day moving average price is $325.56 and its 200-day moving average price is $333.05. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The firm has a market capitalization of $127.33 billion, a price-to-earnings ratio of 34.40, a price-to-earnings-growth ratio of 2.16 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm's revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities research analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker's payout ratio is currently 36.48%.

Insider Buying and Selling

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the business's stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares of the company's stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 315,370 shares of company stock worth $98,463,501 in the last 90 days. Insiders own 4.60% of the company's stock.

Analysts Set New Price Targets

Several analysts recently commented on the company. JPMorgan Chase & Co. dropped their target price on Stryker from $400.00 to $350.00 and set an "overweight" rating on the stock in a report on Friday, July 31st. Truist Financial raised their price objective on shares of Stryker from $330.00 to $340.00 and gave the stock a "hold" rating in a research note on Friday, July 31st. Citizens Jmp cut their target price on shares of Stryker from $440.00 to $400.00 and set a "market outperform" rating for the company in a report on Monday, August 3rd. Robert W. Baird set a $385.00 target price on shares of Stryker in a research note on Friday, May 1st. Finally, Argus set a $370.00 price target on shares of Stryker in a report on Thursday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat, Stryker presently has a consensus rating of "Moderate Buy" and a consensus price target of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source